We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nearly 90 medicines and vaccines in development for HIV/AIDS

Nearly 90 medicines and vaccines in development for HIV/AIDS

December 2, 2011
CenterWatch Staff

America’s biopharmaceutical research companies are testing 88 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

While HIV/AIDS is one of the most devastating diseases affecting people around the world, overall global growth of the disease has stabilized, the number of new infections has been steadily declining, and there are fewer AIDS-related deaths due to the availability of different therapies, such as antiretrovirals, and an enhanced focus on prevention.

Over the past three decades, more than 30 medicines have been approved to treat HIV/AIDS. While these medicines have helped to prolong the lives of HIV-infected patients, it is not enough. America’s biopharmaceutical researchers are focusing on improved treatment regimens, more targeted therapies, and intensifying their efforts to develop preventative vaccines. The International AIDS Vaccine Initiative estimates that a vaccine that is 50% effective and given to only 30% of the population could reduce new HIV infections by 24% over 15 years. Of the 88 medicines and vaccines in development, 49 are antivirals and 27 are vaccines. All of the medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration. They include:

• An antisense gene therapy that uses genetic material derived from HIV-1 itself to remove disease-causing aspects of the virus.

• A transdermal vaccine comprised of DNA plasmids that helps suppress virus replication and destroys HIV-infected cells.

• One treatment in a new class of medicines is intended to prevent the HIV virus from attaching to new cells and breaking through the cell membrane.

HIV/AIDS remains a formidable foe and worldwide epidemic. “The disease poses a complex problem, and we in the biopharmaceutical research industry know as well as anyone that it will require a complex solution,” said PhRMA president and CEO John J. Castellani. “We will find a cure eventually, but in the meantime we continue our efforts to develop new preventative approaches and treatments, so the millions of patients suffering today have a hope of a better tomorrow.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies devoted to inventing medicines that allow patients to live longer, healthier and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010.

 

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing